Literature DB >> 16464970

Optical coherence tomography to monitor photodynamic therapy in pathological myopia.

A García-Layana1, A Salinas-Alamán, M J Maldonado, C Sainz-Gómez, A Fernández-Hortelano.   

Abstract

AIM: To evaluate the role of optical coherence tomography (OCT) in determining choroidal neovascularisation (CNV) activity before and after photodynamic therapy (PDT) in patients with pathological myopia.
METHODS: 33 patients (33 eyes) with pathological myopia and being treated with PDT were included. Every 3 months all patients were evaluated and presence or absence of leakage on fluorescein angiography, presence of intraretinal or subretinal fluid on OCT, and macular and choroidal neovascular complex thickness on OCT, were determined at each examination.
RESULTS: The macular thickness decreased significantly after PDT at 6 months (p = 0.001) and at 12 months follow up (p = 0.01). However, no significant changes in CNV thickness were measured after PDT at 6 months of follow up (p = 0.418) and at 12 months of follow up (p = 0.521). Once the diagnosis of CNV associated with pathological myopia was established, before treatment, OCT had a sensitivity of 96.96% for detecting CNV activity. After treatment, OCT had a good sensitivity (95.23%) and a moderate specificity (69,69%) in determining CNV activity, which resulted in a diagnostic efficiency (proportion of correct results) of 79.62%.
CONCLUSIONS: OCT appears to be useful for indicating CNV activity. Therefore, it may serve as a complementary technique for deciding the need for PDT and re-treatment in patients with pathological myopia.

Entities:  

Mesh:

Year:  2006        PMID: 16464970      PMCID: PMC1857034          DOI: 10.1136/bjo.2005.085555

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization.

Authors:  Rogério A Costa; Michel E Farah; José A Cardillo; Daniela Calucci; George A Williams
Journal:  Retina       Date:  2003-04       Impact factor: 4.256

2.  Pathologic myopia: where are we now?.

Authors:  Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2002-11       Impact factor: 5.258

3.  Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization.

Authors:  Adam H Rogers; Adam Martidis; Paul B Greenberg; Carmen A Puliafito
Journal:  Am J Ophthalmol       Date:  2002-10       Impact factor: 5.258

4.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

Review 5.  Fluorescein angiography complication survey.

Authors:  L A Yannuzzi; K T Rohrer; L J Tindel; R S Sobel; M A Costanza; W Shields; E Zang
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

6.  Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.

Authors:  Irene Barbazetto; Amy Burdan; Neil M Bressler; Susan B Bressler; Laurie Haynes; Anastasios D Kapetanios; Julius Lukas; Karl Olsen; Michael Potter; Al Reaves; Philip Rosenfeld; Andrew P Schachat; H Andrew Strong; Andrea Wenkstern
Journal:  Arch Ophthalmol       Date:  2003-09

7.  [Monitoring the patient after treatment: angiographic aspects of recurrence and indications for retreatment].

Authors:  G Coscas; F Coscas; G Soubrane
Journal:  J Fr Ophtalmol       Date:  2004-01       Impact factor: 0.818

8.  Common causes of blindness and visual handicap in the west of Scotland.

Authors:  I M Ghafour; D Allan; W S Foulds
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

9.  Prevalence of myopia in the United States.

Authors:  R D Sperduto; D Seigel; J Roberts; M Rowland
Journal:  Arch Ophthalmol       Date:  1983-03

10.  Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy. A case report.

Authors:  A Scupola; L Ventura; A C Tiberti; D D'Andrea; E Balestrazzi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-17       Impact factor: 3.117

View more
  5 in total

1.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

2.  Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors:  Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

3.  Pathologic myopia and severe pathologic myopia: correlation with axial length.

Authors:  Ignacio Flores-Moreno; Mariluz Puertas; Elena Almazán-Alonso; Jorge Ruiz-Medrano; María García-Zamora; Rocío Vega-González; José M Ruiz-Moreno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-18       Impact factor: 3.117

4.  Fluorescein Leakage within Recent Subretinal Hemorrhage in Pathologic Myopia: Suggestive of CNV?

Authors:  Lan Mi; Chengguo Zuo; Xiongze Zhang; Bing Liu; Yuting Peng; Feng Wen
Journal:  J Ophthalmol       Date:  2018-08-13       Impact factor: 1.909

5.  Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.

Authors:  Luca Di Antonio; Lisa Toto; Alessandra Mastropasqua; Lorenza Brescia; Emanuele Erroi; Alessia Lamolinara; Marta Di Nicola; Leonardo Mastropasqua
Journal:  Sci Rep       Date:  2018-10-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.